Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trialBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7373.1135 (Published 16 November 2002) Cite this as: BMJ 2002;325:1135
Objective:To assess the cost effectiveness of ultrasound screening for abdominal aortic aneurysms.
Design: Primary analysis: four year cost effectiveness analysis based directly on results from a randomised controlled trial in which patients were individually allocated to invitation to ultrasound screening (intervention) or to a control group not offered screening. Secondary analysis: projection of the data, based on conservative assumptions, to indicate likely cost effectiveness at 10 years.
Setting:Four centres in the United Kingdom. Screening delivered in primary care settings with follow up and surgery offered in the main hospitals
Participants: Population based sample of 67 800 men aged 65-74 years.
Main outcome measures:Mortality from and costs (screening, follow up, elective and emergency surgery) related to abdominal aortic aneurysm; cost per life year gained.
Results:Over four years there were 47 fewer deaths related to abdominal aortic aneurysms in the screening group than in the control group, but the additional costs incurred were £2.2m. After adjustment for censoring and discounted at 6% the mean additional cost of the screening programme was £63.39 ($97.77, €100.48) (95% confidence interval £53.31 to £73.48) per patient. The hazard ratio for abdominal aortic aneurysm was 0.58 (0.42 to 0.78). Over four years the mean incremental cost effectiveness ratio for screening was £28 400 (£15 000 to £146 000) per life year gained, equivalent to about £36 000 per quality adjusted life year. After 10 years this figure is estimated to fall to around £8000 per life year gained.
Conclusions:Even at four years the cost effectiveness of screening for abdominal aortic aneurysms is at the margin of acceptability according to current NHS thresholds. Over a longer period the cost effectiveness will improve substantially, the predicted ratio at 10 years falling to around a quarter of the four year figure.
Editorialsby Greenhalgh and Powell and by Smith
Funding This trial was supported by the UK Medical Research Council and Department of Health. They had no involvement in, or control over, the running of the study, the decision to publish, or the content of this paper. T M Marteau was supported by the Wellcome Trust.
Competing interests None declared.
See web extra for additional material on costing methods
- Accepted 18 October 2002